タイトルまたは説明

Divalproex extended-release tablets Pronunciation
Generic Name: divalproex (dye-VAL-proe-ex)
Brand Name: Depakote ER

Liver failure and death from liver failure has occurred in patients taking divalproex extended-release tablets. This has usually occurred within the first 6 months of treatment. Tell your doctor right away if you notice symptoms of liver problems (eg, a general feeling of discomfort, sluggishness, unusual tiredness or weakness, swelling of the face, loss of appetite, vomiting, stomach pain, dark urine, pale stools, or yellowing of the skin or eyes). In patients who have seizures, loss of seizure control may occur. You should have lab tests done before and during treatment to check for liver problems. Be sure to keep all doctor and lab appointments.

Children younger than 2 years old have an increased risk of fatal liver problems, especially if they take more than 1 seizure medicine or have a metabolic disorder, a severe seizure disorder along with mental retardation, or organic brain disease. Discuss any questions or concerns with your doctor.

There is an increased risk of liver failure and death from liver failure in patients who have a genetic liver problem caused by a mitochondrial disorder (eg, Alpers-Huttenlocher syndrome). You may need to have a special genetic test to check for this condition. Certain patients who have known or suspected mitochondrial disorders should not take divalproex extended-release tablets. Talk with your doctor for more information.

Divalproex extended-release tablets can cause severe birth defects if it is used during pregnancy. It can also cause the child to have a lower IQ. Do not take divalproex extended-release tablets to prevent migraine headaches if you are pregnant. If you are pregnant and take divalproex extended-release tablets for seizures or bipolar disorder, talk to your doctor to decide if you will continue to take divalproex extended-release tablets.

If you are able to become pregnant, you must use an effective form of birth control while you take divalproex extended-release tablets. Contact your doctor right away if you become pregnant or think you may be pregnant while taking divalproex extended-release tablets.

Divalproex extended-release tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get divalproex extended-release tablets refilled.

Severe and sometimes fatal pancreas problems (pancreatitis) have occurred with the use of divalproex extended-release tablets. This has been reported shortly after starting treatment as well as after several years of use. Seek immediate medical attention if you notice any stomach pain, nausea, vomiting, or loss of appetite.
Divalproex extended-release tablets are used for:
Controlling certain types of seizures in the treatment of epilepsy. It is also used to treat the manic phase of bipolar disorder (manic-depressive illness) and prevent migraine headaches. It may also be used for other conditions as determined by your doctor.

Divalproex extended-release tablets are an anticonvulsant. It works by reducing or preventing the number of seizures by controlling the abnormal activity of nerve impulses in the brain and central nervous system. Exactly how it works to treat bipolar disorder and migraine headache is not known.

Do NOT use divalproex extended-release tablets if:
you are allergic to any ingredient in divalproex extended-release tablets
you have liver problems or a urea cycle disorder
you have a genetic liver problem caused by a mitochondrial disorder (eg, Alpers-Huttenlocher syndrome)
the patient is younger than 2 years old and has a mitochondrial disorder
you are taking divalproex extended-release tablets to prevent migraine headaches and you are pregnant
Contact your doctor or health care provider right away if any of these apply to you.

 Advertisement
SLIDESHOW
Epilepsy in Adults: A Healthcare Professional's Guide
Before using divalproex extended-release 
FDA approval given for Divalproex to Indian Drug Company Taj Pharmaceuticals 5th February ***8, Indian Pharmaceuticals Company Taj Pharmaceuticals based in Mumbai announced FDA approval for Divalproex Generic drug manufacturing for regulatory market and non-regulated market. The company is said to have approvals for different combinations of the drug, i.e. Divalproex sodium **0mg, Divalproex sodium **0mg, Divalproex sodium **0mg ER, Divalproex sodium **0mg ER, Divalproex sodium **5mg, Divalproex sodium **0mg, Divalproex sodium ***0mg, Divalproex sodium 1g, Divalproex sodium **0mg ER . The generic manufacturing strategies of New Drug Divalproex and the product-process of Taj Pharmaceuticals Ltd. are compared and collaborated using data from global Pharmaceuticals manufacturing plants in the UK(Newcastle), US, Korea, Italy, Germany and Japan. The Indian company is eminent manufacturer, supplier and exporter of Divalproex and various pharmaceuticals generics medicines in Tablets, capsules, Vial (injections), ampule, Strips and schedule packs etc. The companies integrated research team facilitates the affordable production of the drug for even non-regulated markets of the world. i.e. Middle East, Thailand, Bangladesh etc. The company is also involved in manufacturing of Active Ingredient of various pharmaceuticals finished formulations in IP /BP / USP grades for all markets. The approvals bring a positive uplift in the share market and public perception for Pharmaceuticals investors. Taj Pharmaceuticals Limited Working For Healthier World INDIA FOR IMMEDIATE RELEASE Mumbai - 5th February ***8 - Drug firm Taj Pharmaceuticals today said it has received tentative approval from Food and Drug Administration regulator to sell a generic version of Divalproex Taj Pharma Group announces U SF D A t ent a t i v e ap p r o v a l f o r Va r i ous g ene r i c M ed i c ine s Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. TAJ GROUP © Copyright ***7 Taj Pharma Group (India),. All rights reserved. PHARMACEUTICAL B U S I N E S S Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. © Copyright ***7 Taj Pharma Group (India),. All rights reserved.